Bristol-Myers Squibb Co (BMY) to Issue Quarterly Dividend of $0.45 on August 3rd
Bristol-Myers Squibb Co (NYSE:BMY) announced a quarterly dividend on Thursday, June 11th, Zacks reports. Shareholders of record on Monday, July 6th will be given a dividend of 0.45 per share by the biopharmaceutical company on Monday, August 3rd. This represents a $1.80 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Thursday, July 2nd.
Bristol-Myers Squibb has raised its dividend payment by an average of 90.7% annually over the last three years and has raised its dividend annually for the last 10 consecutive years. Bristol-Myers Squibb has a payout ratio of 29.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Bristol-Myers Squibb to earn $7.35 per share next year, which means the company should continue to be able to cover its $1.80 annual dividend with an expected future payout ratio of 24.5%.
Bristol-Myers Squibb stock opened at $57.98 on Tuesday. The stock has a 50-day moving average of $59.82 and a two-hundred day moving average of $60.91. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.51 and a current ratio of 1.66. Bristol-Myers Squibb has a one year low of $42.48 and a one year high of $68.34. The stock has a market cap of $130.20 billion, a PE ratio of 71.36, a price-to-earnings-growth ratio of 1.11 and a beta of 0.73.
In other news, Director Dinesh C. Paliwal purchased 9,174 shares of the stock in a transaction dated Monday, June 15th. The shares were purchased at an average cost of $54.50 per share, with a total value of $499,983.00. Following the completion of the purchase, the director now directly owns 22,109 shares of the company’s stock, valued at approximately $1,204,940.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Adam Dubow sold 3,200 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $61.01, for a total value of $195,232.00. Following the completion of the sale, the senior vice president now directly owns 16,086 shares in the company, valued at $981,406.86. The disclosure for this sale can be found here. 0.14% of the stock is currently owned by company insiders.
BMY has been the subject of several research analyst reports. Morgan Stanley upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and set a $64.00 price objective for the company in a research note on Thursday, April 2nd. ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Monday, June 1st. William Blair restated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Monday, June 1st. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $66.00 target price on the stock. in a report on Thursday, April 16th. Finally, Cfra raised their target price on Bristol-Myers Squibb from $69.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $68.00.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: What does a hold rating mean?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.